Ropes & Gray advised Novavax in a licensing agreement with Pfizer to develop vaccine products for infectious diseases. The transaction was announced on January 20.
Under the agreement, Pfizer will obtain a non-exclusive license for Novavax’s Matrix-M adjuvant that boosts immune responses for use with Pfizer’s products in up to two disease areas. Pfizer will be responsible for the development and commercialization of its products using Matrix-M. Novavax has the potential to receive up to $530 million in development and sales milestones and is eligible for tiered royalty payments on sales of any Pfizer product that includes Matrix-M.
The Ropes & Gray team included life sciences licensing partner Hannah England and life sciences licensing associate Ian Nilsen.
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.